NEW YORK (GenomeWeb News) - Exact Sciences said on Monday that its board of directors has rejected a bid from Sequenom to buy the company for $1.50 per share in Sequenom common stock.

Exact said that the board agreed unanimously to rebuff Sequenom's proposed acquisition, and that the company is "actively pursuing a strategic alternative" that could offer greater value for shareholders than the Sequenom offer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.